eScreen Explained – Workplace Drug Testing Technology and Services Explained

Workplace drug testing involves more than collecting a urine sample and waiting for results. Behind every screening event there is a chain of custody, a laboratory, a Medical Review Officer, and, increasingly, a software platform that ties all of these pieces together. eScreen occupies a distinct position in this landscape: it is not a clinical laboratory but a technology-enabled Third-Party Administrator (TPA) that manages the operational, administrative, and reporting infrastructure that makes employment drug testing programs function.

This article explains what eScreen is, how it works, who operates it, and what its drug testing services cover in practice.

Company Background and Corporate Structure

eScreen was founded in 1998 by Dr. Murray Lappe and the nation’s largest Medical Review Officer (MRO) corporation. The company was built around a core observation: the vast majority of workplace drug tests return negative results, yet all specimens were historically shipped overnight to a laboratory, adding days to a process that usually had a predictable outcome. eScreen was designed to address that inefficiency by bringing automated, instrument-read screening directly to the collection site.

Originally headquartered in Overland Park, Kansas, with operations in Phoenix, Arizona, eScreen was acquired by Alere, Inc. in 2012 for approximately $270 million in base purchase price (with up to an additional $70 million in contingent consideration). Alere was itself acquired by Abbott, the global healthcare and diagnostics company, in 2017. eScreen now operates under Abbott’s toxicology division. The company’s current offices are in Kansas City, Missouri, and its website carries Abbott’s copyright.

Understanding the corporate structure matters for employers evaluating the system: eScreen provides the technology platform and occupational health network, while the SAMHSA-certified laboratory analysis—required for federally regulated testing—is performed by Alere Toxicology Services, which operates two HHS-certified labs:

Both facilities appear on SAMHSA’s current list of laboratories certified to conduct drug and specimen validity testing for federal workplace drug testing programs.

What eScreen Does: The TPA Model

The distinction between a laboratory and a TPA is important. A laboratory analyzes specimens. A TPA coordinates the broader testing program—ordering tests, managing collection sites, routing specimens, maintaining records, handling chain of custody documentation, and delivering results to employers. eScreen functions as the latter.

In practical terms, eScreen:

This integrated model means that an employer using eScreen does not manage separate relationships with a collection site, a laboratory, and an MRO—those functions are consolidated through eScreen’s platform.

The eScreen Occupational Health Network (EOHN)

eScreen’s collection infrastructure is built on the EOHN, a nationwide network of partner clinics that have been trained and certified to use eScreen’s technology. The EOHN includes more than 5,100 provider locations across the United States, comprising occupational medicine centers, urgent care clinics, emergency rooms, and hospitals.

When a clinic joins the EOHN, it receives:

This network structure means that employers with geographically distributed workforces can maintain a consistent, standardized testing process across all locations.

Core Technology: The eCup+, eReader+, and eScreen123 Platform

eScreen’s most distinctive product is its instrument-read, point-of-collection testing (POCT) system. Most rapid drug tests require a collector to visually interpret a color change on a test strip, a process that introduces subjectivity and privacy concerns. eScreen’s approach automates and removes that subjectivity.

The eCup™+

The eCup+ is a self-contained urine collection cup with reagent test strips embedded in its lid. The donor provides a urine sample directly into the cup; the collector never needs to pour or transfer the specimen into any other container. The lid’s test strips are sensitive to SAMHSA cutoff concentration levels for the drugs being screened.

The eReader™+

The eReader+ is the instrument that reads the eCup+. When the sealed cup is inserted into the device, the eReader uses barcode technology combined with optical imaging to scan the test strips electronically. No one at the collection facility reads or interprets the result—the machine captures it. The eReader also records the specimen’s temperature and tests for common adulterants, including pH, creatinine, and nitrates, to detect attempts to tamper with or substitute the sample.

For negative results, the eReader reports automatically to the employer’s MyeScreen™ portal in as little as 3 to 15 minutes of test completion. Specimens that return a non-negative result are sealed and sent to one of the Alere Toxicology SAMHSA-certified laboratories for confirmatory testing before any action is taken.

eScreen123™ and MyeScreen™

eScreen123 is the collection-site operating software that guides staff step-by-step through every drug-testing event. It manages both non-regulated and regulated (DOT) collections, links the clinic to the testing platform, and supports the electronic chain of custody process.

MyeScreen is the employer-facing web portal where clients can schedule tests, track specimens in real time, receive results, and generate program reports. For regulated (DOT) programs, results flow through MyeScreen once MRO review is complete.

The mCup

For collection sites without an eReader, eScreen also offers the mCup, a manually interpreted urine drug screen cup available in 9- and 11-panel configurations. Like the eCup+, it works within eScreen’s software and electronic chain of custody process, but it relies on a collector visually reading the test strips.

Drug Testing Services

eScreen supports both federally regulated (DOT) and non-regulated (non-DOT) workplace drug testing programs, as well as several specimen types and panel configurations.

Urine Drug Testing

Urine is the primary specimen type in the eScreen system. For non-regulated testing, the eCup+/eReader+ system handles the initial screen at the point of collection. For DOT-regulated testing, specimens are collected using a standard federal paper chain of custody form and shipped to a SAMHSA-certified laboratory for analysis. The eCup+ is not approved for use in federally regulated DOT testing—DOT programs always go directly to the lab.

Lab-based urine testing is also available for non-DOT programs, particularly for employers who want panel configurations beyond what the eCup+ supports, or when regulations in certain states prohibit POCT devices.

Oral Fluid Testing

eScreen offers oral fluid (saliva) testing as a non-regulated option for employers. Oral fluid collection is non-invasive, the sample is collected under direct observation (reducing adulteration risk), and it reflects more recent drug use than urine—generally detecting use within 5 to 48 hours. As noted on eScreen’s own platform, oral fluid is not yet approved for federally regulated workplace drug testing programs.

Hair Drug Testing

Hair testing is available through eScreen’s broader service menu. It provides a significantly longer detection window than urine or oral fluid, with drug metabolites detectable for approximately 90 days in a 1.5-inch head hair sample. Hair testing is not approved for DOT-regulated screening but is used in non-DOT programs where historical drug use patterns are more relevant.

Breath Alcohol Testing

eScreen supports breath alcohol testing, with results logged and reported through eScreen123 and MyeScreen. DOT-regulated non-negative breath alcohol tests must be confirmed on an Evidential Breath Testing (EBT) device by a qualified technician.

Drug Panels and Substances Tested

eScreen supports a range of panel configurations, from the standard federally mandated five-panel to expanded options covering up to 13 substances.

Federally Mandated DOT 5-Panel

Required for safety-sensitive roles regulated by the Department of Transportation, this panel tests for five drug classes and cannot be modified by employers:

Drug Class Metabolite(s) Detected in Urine
Marijuana (THC) THC-COOH (delta-9-tetrahydrocannabinol carboxylic acid)
Cocaine Benzoylecgonine
Opiates Codeine, morphine; confirmatory testing for 6-acetylmorphine (heroin marker)
Amphetamines Amphetamine, methamphetamine; MDMA and related compounds
Phencyclidine (PCP) PCP

Non-DOT Expanded Panels (eCup+ and Lab-Based)

The eCup+ system supports over 100 panel configurations spanning up to 13 drug classes. Employers can select from pre-built panel options or configure their own from the available substances. In addition to the five DOT-standard drug classes, expanded panels may include:

Additional Drug Class Notes
Benzodiazepines Prescription sedatives and anti-anxiety medications (e.g., alprazolam, diazepam)
Barbiturates Central nervous system depressants
Methadone Synthetic opioid; prescribed for pain and addiction treatment
Oxycodone Semi-synthetic opioid; common in prescription misuse
Ecstasy (MDMA) Methylenedioxymethamphetamine; also covers MDA and related compounds
Heroin (6-AM) 6-acetylmorphine, a heroin-specific metabolite
Buprenorphine Synthetic opioid used in addiction treatment (Suboxone)
Propoxyphene Opioid-class analgesic; included in some state programs

The mCup device (manual interpretation) is available in 9- and 11-panel configurations for sites without an eReader.

For any non-negative result—whether from the eCup+, mCup, or direct lab submission—the specimen proceeds to confirmatory testing at a SAMHSA-certified laboratory using GC/MS (gas chromatography/mass spectrometry) or equivalent analytical methods, followed by MRO review before the employer receives a final result.

The Drug Testing Process: How It Works

A standard eScreen-managed non-DOT testing event follows this sequence:

  1. Test Order: The employer orders a test through their account. The donor’s information is registered in the eScreen system prior to their arrival at the collection site.
  2. Identity Verification: The donor arrives at an EOHN clinic. The collector verifies identity by matching the donor against the information entered by the employer.
  3. Specimen Collection: The donor provides a urine sample into the eCup+. The collection is self-contained; no specimen handling is required on the collector’s part.
  4. Automated Instrument Reading: The sealed eCup+ is inserted into the eReader+. The device records temperature, checks for adulterants, reads the test strips, and transmits the result to the eScreen system—all automatically, within minutes.
  5. Negative Result Reporting: If the result is negative, it is reported immediately to the employer’s MyeScreen portal. No further lab processing is needed.
  6. Non-Negative Handling: If the screen is non-negative, the specimen is sealed, documented with an electronic chain of custody form, and shipped to an Alere Toxicology laboratory. The lab performs confirmatory testing by GC/MS or equivalent methodology.
  7. MRO Review: Any confirmed non-negative result is reviewed by a Medical Review Officer—a licensed physician trained in toxicology. The MRO contacts the donor to discuss any legitimate medical explanation (such as a valid prescription) before reporting a final verified result to the employer.
  8. Final Result Delivery: The verified result is delivered to the employer through MyeScreen, completing the process.

Additional Program Management Services

Beyond individual test events, eScreen supports broader workplace drug testing program administration through MyeScreen:

Summary: What eScreen Is and Is Not

eScreen is a specialized technology platform and TPA built specifically for workplace drug testing program management. It is not a clinical reference laboratory and does not process specimens internally. Its value lies in the technology layer—the eCup+/eReader+ instrumented POCT system, the paperless eCCF chain of custody, the eScreen123 collection software, and the MyeScreen reporting portal—and in the nationwide network of occupational health clinics that deploy it.

Employers looking for faster turnaround on negative results, reduced paperwork burden, and consolidated reporting across regulated and non-regulated programs are the primary audience for the eScreen system. For any result that advances beyond the initial screen, standard laboratory analysis and independent MRO review apply—the same scientific and regulatory safeguards that govern all compliant workplace drug testing in the United States.